{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:46:05Z","timestamp":1789911965872,"version":"4.0.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.amjoto.2011.07.012","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T22:31:06Z","timestamp":1315953066000},"page":"349-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia"],"prefix":"10.1016","volume":"33","author":[{"given":"Brian T.","family":"Brinkerhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Treisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Poetker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2011.07.012_bb0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0010","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor\u2013beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"Flieger","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0020","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","article-title":"Bevacizumab in hereditary hemorrhagic telangiectasia","volume":"360","author":"Bose","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1012774","article-title":"Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia","volume":"364","author":"Brinkerhoff","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/lary.21345","article-title":"Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis","volume":"121","author":"Chen","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.dld.2010.10.010","article-title":"Risk\/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis","volume":"43","author":"Galfrascoli","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0040","article-title":"Cardiovascular effects of systemic cancer treatment","author":"Senkus","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/lary.20757","article-title":"Hereditary hemorrhagic telangiectasia\/Avastin","volume":"120","author":"Davidson","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0050","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/lary.20159","article-title":"The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia","volume":"119","author":"Simonds","year":"2009","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2011.07.012_bb0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070911001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070911001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T18:56:52Z","timestamp":1729796212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070911001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0196070911001682"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2011.07.012","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2011.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}